MoonLake Immunotherapeutics Appoints New Officers and Directors

TL;DR

MoonLake beefs up leadership with new CMO & CSO, both joining the board.

AI Summary

MoonLake Immunotherapeutics announced on December 12, 2024, the appointment of Dr. Oliver Schuh as Chief Medical Officer and Dr. Christian Schetter as Chief Scientific Officer. The company also reported the election of Dr. Christian Schetter and Dr. Oliver Schuh to its Board of Directors. These appointments are effective immediately.

Why It Matters

The appointment of key scientific and medical leadership positions is crucial for advancing MoonLake's drug development pipeline and strategic direction.

Risk Assessment

Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events.

Key Players & Entities

• MoonLake Immunotherapeutics (company) — Registrant
• Dr. Oliver Schuh (person) — Appointed Chief Medical Officer and elected to Board of Directors
• Dr. Christian Schetter (person) — Appointed Chief Scientific Officer and elected to Board of Directors
• December 12, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — red Class A ordinary share, par value $0.0001 per share MLTX The Nasdaq Capital M
• $4 m — y grant with a grant date fair value of $4 million, to vest over four years. 1 SI

Filing Documents

• ea0225122-8k_moonlake.htm (8-K) — 33KB
• 0001213900-24-110169.txt ( ) — 201KB
• mltx-20241212.xsd (EX-101.SCH) — 3KB
• mltx-20241212_lab.xml (EX-101.LAB) — 33KB
• mltx-20241212_pre.xml (EX-101.PRE) — 22KB
• ea0225122-8k_moonlake_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Departure On December 12, 2024, Dr. Kara Lassen notified the board of directors (the "Board") of MoonLake Immunotherapeutics (the "Company") of her intent to resign as a member of the Board, effective as of December 31, 2024 (the "Effective Date"), due to the increased responsibilities of her new role at Roche Pharma Research & Early Development. As of the Effective Date, the size of the Board will be reduced from seven to six directors. Dr. Lassen's decision to resign from the Board was not the result of any dispute or disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Company and the Board extend their deepest gratitude to Dr. Lassen for her contributions to the Company. Approval of Long-Term Incentive Program The Board also approved a long-term incentive program consisting of an annual equity grant to certain employees in the form of either restricted stock awards or stock options, depending on the employee's election. As part of that program, in January 2025, Dr. Jorge Santos da Silva, the Chief Executive Officer, Dr. Kristian Reich, the Chief Scientific Officer, and Matthias Bodenstedt, the Chief Financial Officer, are each expected to receive an equity grant with a grant date fair value of $4 million, to vest over four years. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOONLAKE IMMUNOTHERAPEUTICS Date: December 18, 2024 By: /s/ Matthias Bodenstedt Name: Matthias Bodenstedt Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR